Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Devell Young

Internal Medicine Albany, GA Medical Doctor

NPI 1205822657 CMS profile 9777

2002 Palmyra Rd, Suite 101, Albany, GA 31701

Open in the dashboard

General payments

$17,002

1,081 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Devell Young of Albany, GA is reported in the CMS Open Payments database as having received $17,002 across 1,081 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,039 115
2024 General $2,523 141
2023 General $2,721 157
2022 General $2,420 146
2021 General $2,293 149
2020 General $2,136 144
2019 General $2,870 229

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Devell Young
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Devell Young were reported at $2,039. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Devell Young Internal Medicine median Middle half National median
2019 $2,870 $159 $48–$570 $163
2020 $2,136 $119 $33–$402 $114
2021 $2,293 $135 $37–$521 $132
2022 $2,420 $141 $42–$496 $149
2023 $2,721 $149 $45–$519 $160
2024 $2,523 $154 $47–$537 $164
2025 $2,039 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $2,233 127 payments
  2. GlaxoSmithKline, LLC. $1,435 103 payments
  3. AstraZeneca Pharmaceuticals LP $1,380 68 payments
  4. Pfizer Inc. $949 69 payments
  5. Lilly USA, LLC $890 73 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $755 41 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $662 31 payments
  8. Dexcom, Inc. $648 44 payments
  9. Amgen Inc. $639 42 payments
  10. Merck Sharp & Dohme Corporation $588 43 payments
  11. Other $6,824 440 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,778 1,074 payments
  2. Education $224 7 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,597 92 payments
  2. RYBELSUS $1,171 78 payments
  3. TRELEGY ELLIPTA $1,145 84 payments
  4. FARXIGA $1,022 46 payments
  5. Kerendia $662 31 payments
  6. Dexcom G6 Transmitter $606 41 payments
  7. ELIQUIS $509 31 payments
  8. STEGLATRO $461 33 payments
  9. JARDIANCE $460 30 payments
  10. NURTEC ODT $454 26 payments
  11. Other $15,205 1,021 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 178 drugs

Part D claims

13,916

Median for Internal Medicine: 777

Drug cost

$1,748,718

Median for Internal Medicine: $73,373

Branded share of claims

29.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 272 $301,268
Farxiga Dapagliflozin Propanediol Brand 174 $169,518
Mounjaro Tirzepatide Brand 105 $109,992
Tradjenta Linagliptin Brand 94 $104,152
Trulicity Dulaglutide Brand 74 $89,730
Ozempic Semaglutide Brand 80 $84,774
Eliquis Apixaban Brand 70 $75,091
Linzess Linaclotide Brand 91 $68,997
Xarelto Rivaroxaban Brand 68 $59,817
Januvia Sitagliptin Phosphate Brand 66 $53,209

The 10 drugs with the highest cost, of 178 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 84 billing codes

Paid by Medicare

$113,076

Of which drugs: $277

Medicare patients

235

Average age 74

Services billed

7,285

133 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 55%
Arthritis 48%
Diabetes 47%
Cancer 22%
Heart failure 17%
Depression 15%
COPD 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 21 2,280 $221
Injection, ketorolac tromethamine, per 15 mg J1885 Office 19 72 $36

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
$238 272 —
INGREZZA
$226 — —
TRELEGY ELLIPTA
$163 41 —
ELIQUIS
$118 70 —
AIRSUPRA
$118 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

1,081 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record